Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS
出版年份 2019 全文链接
标题
Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS
作者
关键词
-
出版物
CLINICAL DRUG INVESTIGATION
Volume 39, Issue 3, Pages 319-330
出版商
Springer Nature
发表日期
2019-03-05
DOI
10.1007/s40261-018-0735-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
- (2017) S. Cuzzubbo et al. EUROPEAN JOURNAL OF CANCER
- Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review
- (2017) Omar Abdel-Rahman et al. Expert Review of Anticancer Therapy
- Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review
- (2017) Omar Abdel-Rahman et al. Immunotherapy
- Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data
- (2017) Wenjun Wang et al. INTERNATIONAL JOURNAL OF CANCER
- Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients
- (2017) Wei Wei et al. MEDICINE
- Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
- (2017) Laura C. Cappelli et al. ARTHRITIS CARE & RESEARCH
- PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis
- (2017) Jiaying Wu et al. Scientific Reports
- Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis
- (2017) Daniel Y. Wang et al. OncoImmunology
- Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
- (2017) Sarah Chuzi et al. Cancer Management and Research
- Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
- (2016) Vincent Sibaud et al. CURRENT OPINION IN ONCOLOGY
- Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
- (2016) V.R. Belum et al. EUROPEAN JOURNAL OF CANCER
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
- (2016) Lisa Zimmer et al. EUROPEAN JOURNAL OF CANCER
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis
- (2016) Xi Zhang et al. Drug Design Development and Therapy
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- (2016) Camille Hua et al. JAMA Dermatology
- Systematic review: colitis associated with anti-CTLA-4 therapy
- (2015) A. Gupta et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Cardiovascular and pulmonary adverse events in patients treated withBCR-ABLinhibitors: Data from the FDA Adverse Event Reporting System
- (2015) Jorge Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes
- (2015) Mahnaz Mellati et al. DIABETES CARE
- Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System
- (2013) R Harpaz et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
- (2013) Salvatore Maria Corsello et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- (2013) Caroline J. Voskens et al. PLoS One
- Quantitative signal detection using spontaneous ADR reporting
- (2009) A. Bate et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started